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1944How Clinically Relevant Are Treatment
Comparisons of Topical Calcineurin
Inhibitor Trials for Atopic Eczema?
Sally R. Wilkes1, Helen Nankervis1, Elsa Tavernier2, Annabel Maruani3 and Hywel C. Williams1We sought to explore the architecture of trials of calcineurin inhibitors for atopic eczema to document the
extent to which comparisons with active treatments such as topical corticosteroids might have been included
or avoided. We identified all eligible randomized controlled trials using the Global Resource for EczemA Trials
(GREAT) database. Network plots were produced where the nodes represented a treatment type and the lines
between the nodes represented the number of trials or participants involved in the various treatment com-
parisons. A total of 174 randomized controlled trials for atopic eczema treatments were identified in which
pimecrolimus, tacrolimus, or topical corticosteroids were compared with another intervention or a vehicle/
emollient. Of 39 trials involving pimecrolimus and 41 trials involving tacrolimus, 8 (20.5%) and 13 (31.7%),
respectively, made comparisons with topical corticosteroids, and 25 (64.1%) and 15 (36.6%), respectively, were
vehicle-controlled studies. The high rate of comparisons with vehicle controls in randomized controlled trials
that assessed the efficacy of pimecrolimus or tacrolimus long after efficacy had been established is a matter of
concern. Active comparators (mild topical corticosteroids for pimecrolimus and moderate to potent topical
corticosteroids for tacrolimus) are best placed to determine how topical calcineurin inhibitors compare with
established clinical practice.
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Atopic eczema, also known as atopic dermatitis or simply
eczema (Johansson et al., 2004), affects between 0.9% and
24.6% of children worldwide (Odhiambo et al., 2009) and
many adults (Emerson et al., 1998; Yu and Silverberg, 2015).
Topical corticosteroids have been recommended as the first-
line anti-inflammatory treatment for atopic eczema for over
50 years (Eichenfield et al., 2014; Rattner, 1955). Although
their adverse effect profiles are well established and they are
safe when used appropriately, some degree of phobia exists
with their use (Charman et al., 2000). Over the last 10 years,
the topical calcineurin inhibitors pimecrolimus and tacroli-
mus have been introduced as an alternative form of anti-
inflammatory treatment for atopic eczema; they are usually
cited as second-line treatments in various national guidelines
(American Academy of Dermatology, 2016; NICE guidelines,
2014; SIGN Guidelines, 2011). These recommendations are
based on evidence from several randomized controlled trials
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an open access artpimecrolimus and tacrolimus in the treatment of atopic
eczema. However, based on our experience of critically
appraising hundreds of atopic eczema RCTs for various sys-
tematic reviews, it was our impression that relatively few
RCTs compare pimecrolimus or tacrolimus directly with the
first-line treatment of an appropriate-potency topical corti-
costeroid. To explore this impression in more detail, we set
out to examine the geometry of randomized controlled trials
for atopic eczema. Inspired by the work of Maruani et al.
(2015), we developed a network of all atopic eczema RCTs
involving pimecrolimus, tacrolimus, or topical corticoste-
roids in order to see whether there has been an excess of
vehicle-controlled studies to what might be expected in
relation to active comparator studies.
RESULTS
Characteristics of trials
A total of 174 RCTs for atopic eczema treatments were
identified in which pimecrolimus, tacrolimus, or topical
corticosteroids were compared with another intervention or a
vehicle/emollient. Of these, 91 (52.3%) stated that the trial
was either fully or partly funded by industry. Table 1 provides
further details on the characteristics of these RCTs.
Network of trials
The network plot of all comparisons among treatments from
the 174 RCTs is shown in Figure 1, where the size of the node
is proportional to the number of trials involving that inter-
vention, and the thickness of the line is proportional to the
number of trials comparing the two interventions. In total, 24
different interventions were assessed within our network.
Eighty-five (48.9%) trials involved comparison with a vehicle
or emollient.s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Characteristics of atopic eczema RCTs
(N [ 174) involving pimecrolimus, tacrolimus,
or topical corticosteroids
Characteristics of RCTs n (%)
Trials involving
Pimecrolimus 39 (22.4)
Tacrolimus, 0.03% 20 (11.5)
Tacrolimus, 0.01% 22 (12.6)
Tacrolimus, 0.3% 2 (1.1)
Tacrolimus, strength not stated or multiple
strengths used
5 (2.9)
Mild topical corticosteroids 61 (35.1)
Moderate topical corticosteroids 26 (14.9)
Potent topical corticosteroids 65 (37.4)
Very potent topical corticosteroids 2 (1.1)
Sample size, median (interquartile range) 71 (30, 200.5)
Trials involving
Children < 18 years old only 67 (38.5)
Adults  18 years old only 55 (31.6)
Children and adults 47 (27.0)
Not stated 5 (2.9)
Design of the trial
Parallel 71 (40.8)
Within person/split body 44 (25.3)
Crossover 5 (2.9)
Unclear/not stated 54 (31.0)
Study funding
Industry funded (either fully or in part) 91 (52.3)
Non-industry funded (e.g., solely charity or
government funded)
11 (6.3)
Not stated 72 (41.4)
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Network Geometry of Atopic Eczema TrialsA second network plot is given in Supplementary Figure S1
online, where the size of the node is proportional to the total
number of patients who received that intervention across all
trials, and the thickness of the line is proportional to the
number of patients who were involved in trials comparing the
two interventions.
Several comparisons between interventions were over-
represented in the network. This was reflected in the co-
occurrence analysis, which yielded a significant observed
C-score of 111.6, with a 95% confidence interval of the
simulated C-score under the null hypothesis of 109.6 to
111.3 (P-value ¼ 0.003). The upper confidence interval value
of the simulated C-score is lower than the observed C-score,
meaning that there exists a higher degree of co-occurrence
than in the null hypothesis, the null hypothesis being that
the pattern in the choices of treatment comparisons within
the network is random.
Table 2 details the number of comparisons that were made
among pimecrolimus, tacrolimus, topical corticosteroids,
and vehicle/emollient. The most clinically relevant compar-
ators for pimecrolimus are mild and moderate topical corti-
costeroids (NICE guidelines, 2014). Pimecrolimus was
compared with mild topical corticosteroids in one trial and
with moderate topical corticosteroids in three trials (2.6%
and 7.7% of all trials in the network that involved pimecro-
limus, respectively). In contrast, pimecrolimus was compared
with a vehicle or emollient in 25 trials (64.1% of all trials inthe network that involved pimecrolimus). Five (20%) of the
25 vehicle-controlled trials involved patients with moderate
to severe atopic eczema, and 21 (84%) declared that they
were funded in full or in part by industry.
For topical tacrolimus, the most clinically relevant com-
parators are mild and moderate topical corticosteroids for
0.03%-strength tacrolimus and moderate and potent topical
corticosteroids for 0.1%-strength tacrolimus. Tacrolimus was
compared with mild topical corticosteroids in seven trials
(one involved 0.03%-strength tacrolimus, four involved
0.1%-strength tacrolimus, and two involved both 0.03% and
0.1%), with moderate topical corticosteroids in two trials
(both involved 0.1% tacrolimus), and with potent topical
corticosteroids in eight trials (three involved 0.03%-strength
tacrolimus, four involved 0.1%-strength tacrolimus, and one
did not state the strength of tacrolimus used). Fifteen (36.6%)
of all 41 trials involving tacrolimus involved a comparison
with a vehicle control. Ten (66.7%) of the 15 vehicle-
controlled trials involved patients with moderate to severe
atopic eczema, and 10 (66.7%) declared that they were
funded in full or in part by industry.
DISCUSSION
Main findings
Clinicians need good information to make the best treatment
choices with their patients in a shared decision-making
model. When a new treatment is introduced, clinicians
ideally want to know, “Is this new treatment better in some
way than the treatments that I already use?” In the case of
topical calcineurin inhibitors, such a practical question re-
quires comparison with existing topical corticosteroids rather
than vehicle. Vehicle-controlled studies are, of course,
needed early on in the development of new drugs to deter-
mine treatment efficacy and safety. Before a new drug comes
onto the market, efficacy and safety have to be established for
licensing purposes, typically through a program of phase II
studies and subsequent phase III studies. Pivotal phase III
studies are typically large vehicle-controlled studies initially,
followed by studies against active comparators later. One can
understand the need for four or maybe five vehicle-controlled
trials for topical pimecrolimus and tacrolimus to establish
efficacy and safety in different populations such as children
versus adults, Hispanics and blacks compared with white
populations, and in a few different countries where treatment
pathways might differ.
The network map produced in this study suggests an
overkill of vehicle-controlled studies for topical pimecroli-
mus (25 trials, 64%) and, to a lesser extent, topical tacrolimus
(15 trials, 36.6%). The scientific and ethical justifications for
so many vehicle-controlled studies need to be questioned,
given that scientific equipoise in favor of the active drug is
clear after pivotal studies have been performed. Others have
commented that the promulgation of so many vehicle-
controlled studies may be construed by some as being un-
necessary and a form of marketing—so-called “seeding trials”
(Alexander, 2011; Eheberg et al., 2015; Lexchin, 2013; Rose
and Kopp, 2015).
Of the trials involving a comparison between pimecroli-
mus and vehicle/emollient, tacrolimus and vehicle/emollient,
or topical corticosteroids and vehicle/emollient, 84%,www.jidonline.org 1945
Figure 1. Network of randomized controlled trials for atopic eczema involving pimecrolimus, tacrolimus, or topical corticosteroids. Nodes represent the
interventions—two nodes are linked together with a line if at least one trial compared the two interventions. The size of the node is proportional to the number of
trials involving that intervention. Similarly, the thickness of the line is proportional to the number of trials comparing the two interventions. The lines are labeled
with the number of comparisons if the number was greater than 1. “Any TCS” represents interventions where participants were allowed to apply any potency of
topical corticosteroid. “Any tacrolimus” represents interventions where participants were allowed to apply any strength of tacrolimus or where the study did not
state the strength of tacrolimus used. TCS, topical corticosteroids.
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194666.7%, and 45.7%, respectively, declared that they were
funded either in full or in part by industry. Several studies
have shown that RCTs sponsored by industry are more likely
to produce results in favor of the product made by that
company (Katz et al., 2006; Lexchin et al., 2003). In addition,
evidence also shows that industry-sponsored trials are more
likely to compare an intervention against an inactive or
“straw man” comparator (Ioannidis and Karassa, 2010;
Stamatakis et al., 2013).
The use of network plot for reviewing research priorities
Constructing this network of evidence is a method that can
enable researchers and clinicians to have a complete picture
of the evidence for pimecrolimus, tacrolimus, and topical
corticosteroids and alert them to treatment comparisons that
have not been directly compared in RCTs. The network has
also highlighted areas that currently lack evidence, whichJournal of Investigative Dermatology (2016), Volume 136will hopefully provide a clearer direction for future research
into treatments for atopic eczema.
Strengths and limitations
Our study has some limitations. It is possible that we could
have missed some unpublished studies of active comparators
that did not show favorable results. We did not assess the
severity of atopic eczema in each individual RCT, nor did we
assess any other patient characteristics, such as age. We also
did not write to all of the companies involved to ask for their
reasons why so many vehicle-controlled studies were done. It
is possible, for example, that some countries required new
additional vehicle studies to be done in their own pop-
ulations, despite a large volume of clear evidence of efficacy
from vehicle-controlled studies from other countries. It is
possible that other new treatments for atopic eczema have or
will illustrate a similar profusion of vehicle-controlled
Table 2. Number of trials comparing topical corticosteroids, pimecrolimus, tacrolimus, and vehicle/emollient
Trial Type n (%)1
Funded by Industry,
n (%)
Noncommercially Funded,
n (%)
Unknown Funder,
n (%)
Trials (n ¼ 39) comparing pimecrolimus with
Mild TCS 1 (2.6) 0 (0.0) 0 (0.0) 1 (100.0)
Moderate TCS 3 (7.7) 2 (66.7) 0 (0.0) 1 (33.3)
Potent TCS 4 (10.3) 2 (66.7) 1 (33.3) 1 (33.3)
Tacrolimus, 0.03% 2 (5.1) 2 (100.0) 0 (0.0) 0 (0.0)
Tacrolimus, 0.1% 3 (7.7) 3 (100.0) 0 (0.0) 0 (0.0)
Any tacrolimus 1 (2.6) 0 (0.0) 0 (0.0) 1 (100.0)
Vehicle/emollient 25 (64.0) 21 (84.0) 0 (0.0) 4 (16.0)
Trials (n ¼ 20) comparing 0.03% tacrolimus with2
Mild TCS 3 (15.0) 3 (100.0) 0 (0.0) 0 (0.0)
Potent TCS 3 (15.0) 2 (66.7) 0 (0.0) 1 (33.3)
Any TCS 1 (5.9) 0 (0.0) 0 (0.0) 1 (100.0)
Vehicle/emollient 11 (55.0) 8 (72.7) 0 (0.0) 3 (27.3)
Trials comparing 0.1% tacrolimus with2
Mild TCS 6 (27.3) 5 (83.3) 0 (0.0) 1 (16.7)
Moderate TCS 2 (10.0) 1 (50.0) 1 (50.0) 0 (0.0)
Potent TCS 3 (15.0) 3 (100.0) 0 (0.0) 0 (0.0)
Tacrolimus and potent TCS 1 (5.0) 1 (100.0) 0 (0.0) 0 (0.0)
Vehicle/emollient 7 (31.8) 6 (85.7) 0 (0.0) 1 (14.3)
Trials (n ¼ 2) comparing tacrolimus 0.3% with2
Vehicle/emollient 2 (100.0) 2 (100.0) 0 (0.0) 0 (0.0)
Trials comparing mild TCS with
Moderate TCS 9 (14.5) 2 (22.2) 0 (0.0) 7 (77.8)
Potent TCS 17 (27.4) 6 (35.3) 1 (5.9) 10 (58.8)
TCS plus another intervention 6 (9.7) 2 (33.3) 1 (16.6) 3 (50.0)
Vehicle/emollient 15 (24.2) 6 (40.0) 3 (20.0) 6 (40.0)
Other type of intervention 7 (11.3) 4 (57.1) 0 (0.0) 3 (42.9)
Trials (n ¼ 26) comparing moderate TCS with
Potent TCS 6 (23.1) 0 (0.0) 0 (0.0) 6 (100.0)
Vehicle/emollient 5 (19.2) 2 (40.0) 0 (0.0) 3 (60.0)
Other type of intervention 1 (3.8) 0 (0.0) 0 (0.0) 1 (100.0)
Trials comparing potent TCS with
Any tacrolimus 1 (1.6) 0 (0.0) 0 (0.0) 1 (100.0)
Very potent TCS 1 (1.6) 0 (0.0) 0 (0.0) 1 (100.0)
TCS plus another intervention 3 (4.8) 0 (0.0) 0 (0.0) 3 (100.0)
Vehicle/emollient 21 (33.9) 10 (47.6) 3 (14.3) 8 (38.1)
Other type of intervention 3 (4.8) 1 (33.3) 1 (33.3) 1 (33.3)
Abbreviation: TCS, topical corticosteroids.
1Not all of the columns for each intervention will add up to the total number shown. This is because comparisons are not repeated down the table. For
example, the numbers for pimecrolimus compared with mild TCS are given in the pimecrolimus section and therefore are not repeated under the mild TCS
section of the table.
2Some trials involved more than one strength of tacrolimus. There were 41 trials in total that involved tacrolimus.
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introduced over the last 20 years. One could argue that topical
corticosteroids have also been overly compared against
vehicle preparations, and that may be so (46 [36.2%] of 127
involving topical corticosteroids made comparisons with a
vehicle control). However, it should be recognized that 27
different types of topical corticosteroids have been included in
the corresponding nodes in Figure 1, whereas topical pime-
crolimus is just one preparation and topical tacrolimus is just
three strengths of the same preparation. Strengths of our study
include the comprehensive inclusion of all published clinical
trials obtained through the Global Resource for EczemA Trials
(GREAT) database covering the entire period in which the two
topical calcineurin inhibitors were introduced.Implications for clinical practice and future research
Clinicians and clinical scientists need to become more
involved in designing and participating in drug trials when
new drugs are introduced and should ask how many vehicle-
controlled studies have been done and how many more are
really needed and for what purpose. Four or five placebo/
vehicle studies might be enough, even for a global market.
Such an ideal might be difficult to realize, given that clinical
investigators are typically paid well for recruiting patients
into such studies. Regulatory bodies might do more to
encourage more active comparisons for phase III studies,
using appropriate existing competitor products at the correct
dose and frequency. Ethical committees should also question
how many vehicle-controlled studies have been done beforewww.jidonline.org 1947
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1948granting permission for more such studies. Most important of
all, the public can be made more aware of the difference
between vehicle-controlled and active comparator trials so
that they too can make a judgement of when enough is
enough when comparing a new active topical drug against
vehicle, especially for those who have moderate to severe
disease.
In addition to suggesting a rebalance toward more active
rather than placebo- or vehicle-controlled studies, greater
emphasis should be placed on the choice of outcomes, such
as the core outcome set currently being developed by the
Harmonising Outcomes in Eczema initiative, so that studies
can be compared directly against each other in systematic
review meta-analyses (Schmitt et al., 2015). In addition to
efficacy outcomes, safety outcomes should also be recorded
and reported. For example, the main rationale for bringing
topical calcineurin inhibitors onto the market was concern
about possible adverse effects of topical corticosteroids such
as skin thinning, yet clinically significant skin thinning has
rarely been reported in such trials. In the largest clinical trial
of topical pimecrolimus compared against mild to moderate
topical corticosteroids over a long period, the frequency of
clinical skin thinning was just one out of 1,213 children for
those using long-term topical corticosteroids compared with
zero out of 1,205 in the topical pimecrolimus group—that is,
no real difference at all (Sigurgeirsson et al., 2015). However,
extracting such key information from the trialists took three
attempts by different correspondents, and the key data
remain buried in the online correspondence section of the
journal.
There is no doubt that the pharmaceutical industry is
needed and that it has been responsible for some key in-
novations in dermatology, including the topical calcineurin
inhibitors for treating atopic eczema at sensitive sites and for
preventing flares (Schmitt et al., 2011). Active rather than
passive engagement in drug development from a whole range
of constituencies is now needed for new drug developments
in dermatology.MATERIALS AND METHODS
GREAT database
The GREAT database contains records of all RCTs and systematic
reviews of treatments for atopic eczema published since the inception
of the MEDLINE (1966) and EMBASE (1980) (Centre of Evidence
Based Dermatology, 2013). The search strategy used to populate the
GREAT database is given in Supplementary Table S1 online. Searches
are also carried out using the Cochrane Library and the Cochrane Skin
Group specialized register of trials from inception; therefore, the
GREAT database also contains many records that are not in MEDLINE
or EMBASE as a result of handsearching and other searches done by
the Cochrane Skin Group. Further information on the GREAT data-
base can be found at http://www.greatdatabase.org.uk.
Selection criteria
The GREAT database was searched to identify all RCTs for atopic
eczema up through 4 December 2014 that incorporated at least one
treatment arm involving pimecrolimus, tacrolimus, or topical corti-
costeroids as an intervention. Any RCTs that involved only intradrug
comparisons—for example, different doses of the same drug—wereJournal of Investigative Dermatology (2016), Volume 136excluded because we believed it unlikely that these dose-finding
studies would have deliberately avoided a lower or standard dose.
Categorization of interventions
All doses and regimens of pimecrolimus were grouped together.
Tacrolimus was categorized in strengths of 0.03%, 0.1% and 0.3%.
Trials for which the strength of tacrolimus was not stated or partici-
pants were allowed to use multiple different strengths within the trial
were classified as “any tacrolimus.” Topical corticosteroids were
grouped according to potency (mild, moderate, potent, or very
potent) using the British National Formulary (Joint Formulary
Committee, 2016). Trials that allowed for any potency of topical
corticosteroid to be used as an intervention were categorized in a
separate group called “any topical corticosteroid.” Interventions
involving combined therapies were grouped—for example, all in-
terventions of topical corticosteroids plus an antimicrobial were
grouped together. Where topical corticosteroids were combined with
another therapy, the potency was ignored for the purpose of catego-
rization. Emollients and vehicles were grouped together as a topical
intervention without the active principle. Further details of all the
intervention categories are given in Supplementary Table S2 online.
Trial networks
A network of all comparisons between treatments from the RCTs
identified in our search was developed. Two network plots were
produced in which the nodes represented the interventions and the
lines linking the nodes represented a comparison between the two
interventions being linked. In the first plot, the size of the node was
proportional to the number of trials involving that intervention, and
the thickness of the line was proportional to the number of trials
comparing two interventions. In the second plot, the size of the node
was proportional to the total number of patients who received that
intervention across all trials. Similarly, the thickness of the line was
proportional to the number of patients involved in trials comparing
the two interventions.
Trials involving more than two treatment arms of different thera-
peutic classes were allowed to contribute to the network more than
once. For example, a three-arm trial comparing pimecrolimus, tacro-
limus, and vehicle contributed to the lines linking pimecrolimus and
tacrolimus, pimecrolimus and vehicle, and tacrolimus and vehicle.
Co-occurrence
To determine whether some head-to-head comparisons of specific
interventions were avoided or preferred, the degree of co-occurrence
was assessed using the C-score statistic (Stone and Roberts, 1990).
The C-score is estimated by first examining each particular pair of
treatments within the network. The number of times each of the two
treatments appear in the network is noted, along with the number of
times the two treatments are directly compared. This gives an idea of
how many times the two treatments could have been compared,
given their relative frequencies. The C-score statistic is obtained by
averaging over all possible pairs of treatments in the network.
Therefore, the C-score reflects the tendency for treatment compari-
sons not to occur in the network. A larger C-score corresponds to a
larger degree of co-occurrence in the network, meaning that there is
more likely to be a selective pattern in the choices of treatment
comparisons within the network (Salanti et al., 2008).
To assess the statistical significance of the C-score statistic,
a permutations procedure is applied that asks the underlying ques-
tion: Given the number of studies in our network, each comparing
two treatments, and given the number of times each of those
SR Wilkes et al.
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the estimated C-score statistic? This procedure produces a 95%
confidence interval and a P-value for the estimated C-score under
the null hypothesis that there is no selective pattern in the network. A
significant P-value (<0.05) indicates that the estimated C-score is
unlikely to be attributable to chance and that there are selective
patterns in the choices of treatment comparisons in the network.
Analyses were carried out using R software, version 3.1.0 (R Core
Team, Vienna, Austria), with the package EcoSimR and the NodeXL
add-in with Excel.
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